Moreover, Ruggeri et al. showed that pre-transplant alloreactive Ly49 (Ly49 receptors recognize major histocompatibility complex (MHC) class I molecules in mice, which is analogous to KIR in humans) ligand-mismatched donor NK cell transfusion successfully eliminated host tumor cells and protected against GVHD by depleting host APCs. The gene discussed is KIR3DL1; the disease is neoplasm.